Bipolar DisorderPhase 3NCT00107926
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
A Phase 3 study testing Licarbazepine in people with Bipolar Disorder, run by Novartis Pharmaceuticals at 44 sites in 13 countries.
Trial summary
The purpose of this study is to evaluate the effectiveness and tolerability of an investigational drug for the treatment of manic episodes of bipolar disorder. The investigational drug will be given as additional treatment with either lithium or valproate, which are already FDA (Food and Drug Administration)-approved… Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Bipolar Disorder
- What is being tested?
- Licarbazepine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 343 participants
- Where
- 44 sitesin 13 countries
- Study dates
- Oct 2004to Aug 2007
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of bipolar disorder (type I) with manic or mixed episodes (including patients with/without psychotic features or with/without a history of rapid cycling)
- In need of psychiatric treatment
- Cooperation and willingness to complete all aspects of the study
Who cannot join
- Current diagnosis other than bipolar I disorder
- History of schizophrenia or schizoaffective disorder
- Drug dependence within 1 month prior to study start or testing positive in a urine drug test
- Suicide attempt within 1 month prior to study start or at immediate risk of harm to self or others
- Any form of psychotherapy within 1 month prior to study start
Trial locations and contacts
44 sites in 13 countries.
44 sites in 13 countries
United States12 sites
Investigational Site
Bellaire, Texas, 77401
Investigational Site
Bellevue, Washington, 98004
Investigational Site
Dallas, Texas, 75235
Investigational Site
Farmington Hills, Michigan, 48334
Investigational Site
Kansas City, Kansas, 66160
Investigational Site
Kirkland, Washington, 98033
Investigational Site
La Palma, California, 90623
Investigational Site
Madison, Tennessee, 37115
Investigational Site
Shreveport, Louisiana, 71101
Investigational Site
Somerville, Massachusetts, 02143
Investigational Site
Staten Island, New York, 10305
Investigational Site
West Allis, Wisconsin, 53227
Canada6 sites
Novartis investigator site
Greater Sudbury
Novartis Investigational Site
Kelowna
Novartis investigator site
London
Novartis investigator site
Montreal
Novartis investigator site
Vancouver
Novartis investigator site
Verdun
Germany6 sites
Novartis Investigational Site
Berlin
Novartis Investigational Site
Bochum
Novartis Investigational Site
Dresden
Novartis Investigational Site
Ingolstadt
Novartis Investigational Site
Mannheim
Novartis Investigational Site
Würzburg
Ukraine5 sites
Novartis Investigational Site
Dnipro
Novartis Investigational Site
Kiev
Novartis Investigational Site
Luhansk
Novartis Investigational Site
Odesa
Novartis Investigational Site
Simferopol
Czechia3 sites
Novartis Investigational Site
Brno
Novartis Investigational Site
Hradec Králové
Novartis Investigational Site
Prague
Russia2 sites
Novartis Investigational Site
Moscow
Novartis Investigational Site
Yaroslavl
Slovakia2 sites
Novartis Investigational Site
Bojnice
Novartis Investigational Site
Michalovce
About this study
The purpose of this study is to evaluate the effectiveness and tolerability of an investigational drug for the treatment of manic episodes of bipolar disorder. The investigational drug will be given as additional treatment with either lithium or valproate, which are already FDA (Food and Drug Administration)-approved treatments for mania.
- Conditions
- Bipolar Disorder
- Being tested
- Licarbazepine, Placebo
- Keywords
- bipolar disorder, manic episode, treatment, licarbazepine
- Medical subject headings
- Bipolar Disorder, Mania
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LicarbazepineDrug
PlaceboDrug
| Study group | Role | What they receive |
|---|---|---|
| licarbazepine | Experimental | Not described Receives: Drug: Licarbazepine |
| Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean reduction in manic episodes and major depressive episodes from baseline to endpoint (week 6).
Secondary outcomes (1)
Major improvement in anxiety and depression from baseline to endpoint (week 6)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Apr 2005 (estimated)
- Study startOct 2004
- Primary completionAug 2007
- Study completionAug 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bipolar DisorderStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 343 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Novartis Pharmaceuticals, Study director, Novartis Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00107926
- Sponsor's protocol ID
- CLIC477D2303
- Status last verified
- Mar 2017
- First submitted
- 11 Apr 2005
- Last updated
- 22 Mar 2017
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Mar 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
- ClinicalTrials.gov ID
- NCT00107926
- Acronym / sponsor ID
- CLIC477D2303
- Conditions
- Bipolar Disorder
- Keywords
- bipolar disorder, manic episode, treatment, licarbazepine
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 343 participants (actual)
- Lead sponsor
- Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- Oct 2004
- Primary completion
- Aug 2007 (actual)
- Study completion
- Aug 2007 (actual)
- First posted
- 12 Apr 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the effectiveness and tolerability of an investigational drug for the treatment of manic episodes of bipolar disorder. The investigational drug will be given as additional treatment with either lithium or valproate, which are already FDA (Food and Drug Administration)-approved treatments for mania.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| licarbazepine | Experimental | Drug: Licarbazepine |
| Placebo | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Diagnosis of bipolar disorder (type I) with manic or mixed episodes (including patients with/without psychotic features or with/without a history of rapid cycling)
- In need of psychiatric treatment
- Cooperation and willingness to complete all aspects of the study
Key exclusion criteria (5 listed)
- Current diagnosis other than bipolar I disorder
- History of schizophrenia or schizoaffective disorder
- Drug dependence within 1 month prior to study start or testing positive in a urine drug test
- Suicide attempt within 1 month prior to study start or at immediate risk of harm to self or others
- Any form of psychotherapy within 1 month prior to study start
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Licarbazepine | Drug | licarbazepine |
| Placebo | Drug | Placebo |
Primary outcome
Mean reduction in manic episodes and major depressive episodes from baseline to endpoint (week 6).
1 secondary outcome
Major improvement in anxiety and depression from baseline to endpoint (week 6)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Mar 2017.
- Click here for further information and to find an investigational site near youLink provided by the sponsor.
Related trials for Bipolar Disorder
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Recruiting
Safety and Feasibility of DBS for Bipolar Depression
Bipolar I Disorder, Bipolar Depression
Not yet recruiting
Compulsive Eating and Brain's Reward System in Different Pathologies
PARKINSON DISEASE (Disorder), Bipolar 1 Disorder
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Recruiting
Affective Cognitive Training in Mood Disorders and High-risk Relatives
Major Depressive Disorder (MDD), Bipolar Disorder (BD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Novartis Pharmaceuticals study director
Novartis Pharmaceuticals
44 sites in 13 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Licarbazepine in people with Bipolar Disorder, run by Novartis Pharmaceuticals at 44 sites in 13 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 44 sites in United States, Canada, Germany, Ukraine, Colombia and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean reduction in manic episodes and major depressive episodes from baseline to endpoint (week 6).. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Mar 2017; AzTrials last refreshed its copy on 8 Nov 2026.